Agilent Sheds Hycor Biomedical Business | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Private equity firm Linden LLC has paid an undisclosed sum to purchase the Hycor Biomedical business of Agilent Technologies.

Hycor, which specializes in allergy, autoimmune, and urinalysis diagnostics, became part of Agilent through that firm's 2007 acquisition of Stratagene. Hycor had only been part of Stratagene for a few years before the deal with Agilent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.